SCHEMBL4653544

SCHEMBL4653544

COC(=O)c1ccc(OC/C=C(\C)CCC=C(C)C)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.64
MAOA P21397 1/20 0.64
ALOX15 P16050 4/20 0.53
TDP1 Q9NUW8 2/20 0.53
KDM4E B2RXH2 1/20 0.53
NDUFS8 O00217 1/20 0.53
COXFA4 O00483 1/20 0.53
NDUFAB1 O14561 1/20 0.53
NDUFA1 O15239 1/20 0.53
NDUFS4 O43181 1/20 0.53
NDUFB5 O43674 1/20 0.53
NDUFB3 O43676 1/20 0.53
NDUFC1 O43677 1/20 0.53
NDUFA2 O43678 1/20 0.53
NDUFS5 O43920 1/20 0.53
NDUFS7 O75251 1/20 0.53
NDUFS2 O75306 1/20 0.53
NDUFS6 O75380 1/20 0.53
NDUFB1 O75438 1/20 0.53
NDUFS3 O75489 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4653546 1.00 MAOB (0.64) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL4652315 0.99 MAOB (0.63) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL4652309 0.99 MAOB (0.63) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL5844088 0.91 TRPV1 (0.54) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL5844089 0.91 TRPV1 (0.54) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL4653838 0.88 MAOB (0.52) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL4653841 0.88 MAOB (0.52) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL3303212 0.88 MAOB (0.55) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL3302293 0.88 MAOB (0.55) MAOBMAOAALOX15TDP1KDM4E
SCHEMBL4652411 0.87 ALOX15 (0.56) MAOBMAOAALOX15TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5646184-A SEBACEOUS SECRETION INHIBITORY ACTIVITY KAO CORPORATION (JP) 1997-07-08 US claimed
EP-1602354-B1 Use of polyglutamic acid or its salts MEIJI SEIKA KAISHA (JP) 2008-11-05 EP disclosed
EP-1604647-B1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof CHISSO CORP (JP) 2008-05-07 EP disclosed
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair MEIJI SEIKA KAISHA, LTD. (JP) 2006-07-27 US disclosed
US-20060018867-A1 Cosmetic composition and production thereof ICHIMARU PHARCOS CO., LTD 2006-01-26 US disclosed
EP-1604647-A1 Cosmetic composition containing polyorganosiloxane-containing epsilon-polylysine polymer, and polyhydric alcohol, and production thereof Ichimaru Pharcos Co., Ltd. (JP) 2005-12-14 EP disclosed
EP-1602354-A1 HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR Meiji Seika Kaisha, Ltd. (JP) 2005-12-07 EP disclosed
EP-0643035-B1 DERMATOLOGIC PREPARATION AND NOVEL BENZOIC ACID DERIVATIVE KAO CORP (JP) 1999-09-01 EP disclosed
US-5646184-A SEBACEOUS SECRETION INHIBITORY ACTIVITY KAO CORPORATION (JP) 1997-07-08 US disclosed
WO-1996017589-A1 METHOD OF SMOOTHING OR REMOVING WRINKLES AND METHOD OF STIMULATING COLLAGEN SYNTHESIS KAO CORPORATION (JP) 1996-06-13 WO disclosed
EP-0643035-A1 DERMATOLOGIC PREPARATION AND NOVEL BENZOIC ACID DERIVATIVE Kao Corporation (JP) 1995-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060165636-A1 Hair treatment composition and hair cosmetic for damaged hair CUTA, COL14A1, PRKDC MAOB 3870/4885MAOA 2654/4885ALOX15 3447/4885
US-20060018867-A1 Cosmetic composition and production thereof CUTA, PARG, TYR MAOB 299/4885MAOA 174/4885ALOX15 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.